内射人妻无码色AV天堂,BAOYU最新无码网站在线观看,亚洲AV无码一区二区三区网站,欧洲女人牲交视频免费

更用心，只為更好地護(hù)佑健康

我們將對(duì)患者的關(guān)懷體現(xiàn)在藥物生產(chǎn)和運(yùn)轉(zhuǎn)的全過程細(xì)節(jié)把控中
Inhixa
通用名：
依諾肝素鈉注射液
銷售市場：
歐盟非波蘭
規(guī)格：
2,000?IU?(20?mg)/0.2?mL 4,000 IU (40 mg)/0.4 mL 6,000 IU (60 mg)/0.6 mL 8,000 IU (80 mg)/0.8 mL 10,000 IU (100 mg)/1.0 mL 12,000?IU (120?mg)/0.8?mL 15,000?IU (150?mg)/1?mL 30,000?IU (300?mg)/3?mL 50,000?IU (500?mg)/5?mL 100,000 IU (1000 mg)/10 mL
適應(yīng)癥：
Inhixa is indicated in adults for:

·Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.

·Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.

·Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.

·Prevention of thrombus formation in extra corporeal circulation during haemodialysis.

·Acute coronary syndrome:

·Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.

·Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).